Protalix BioTherapeutics, Inc. (NYSE:PLX) has 1 institutional investors that have filed 13F reports for the period ending March 2020.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 31 Dec, 2025 | 4,956,352 | 2,375,796 | 92.07% | $8,921,434.00 |
| Opaleye Management Inc. | 31 Dec, 2025 | 4,956,352 | 2,375,796 | 92.07% | $8,921,434.00 |
| Opaleye Management Inc. | 31 Dec, 2025 | 4,956,352 | 2,375,796 | 92.07% | $8,921,434.00 |
| Opaleye Management Inc. | 31 Dec, 2025 | 4,956,352 | 2,375,796 | 92.07% | $8,921,434.00 |
| Opaleye Management Inc. | 31 Dec, 2025 | 4,956,352 | 2,375,796 | 92.07% | $8,921,434.00 |
| BlackRock, Inc. | 31 Dec, 2025 | 3,647,106 | 96,078 | 2.71% | $6,564,791.00 |
| BlackRock, Inc. | 31 Dec, 2025 | 3,647,106 | 96,078 | 2.71% | $6,564,791.00 |
| BlackRock, Inc. | 31 Dec, 2025 | 3,647,106 | 96,078 | 2.71% | $6,564,791.00 |
| BlackRock, Inc. | 31 Dec, 2025 | 3,647,106 | 96,078 | 2.71% | $6,564,791.00 |
| BlackRock, Inc. | 31 Dec, 2025 | 3,647,106 | 96,078 | 2.71% | $6,564,791.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Dec, 2025 | 1,263,300 | -52,100 | -3.96% | $2,273,940.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Dec, 2025 | 1,263,300 | -52,100 | -3.96% | $2,273,940.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Dec, 2025 | 1,263,300 | -52,100 | -3.96% | $2,273,940.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Dec, 2025 | 1,263,300 | -52,100 | -3.96% | $2,273,940.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Dec, 2025 | 1,263,300 | -52,100 | -3.96% | $2,273,940.00 |
| Northern Trust Corp | 31 Dec, 2025 | 865,708 | -36,751 | -4.07% | $1,558,274.00 |
| Northern Trust Corp | 31 Dec, 2025 | 865,708 | -36,751 | -4.07% | $1,558,274.00 |
| Northern Trust Corp | 31 Dec, 2025 | 865,708 | -36,751 | -4.07% | $1,558,274.00 |
| Northern Trust Corp | 31 Dec, 2025 | 865,708 | -36,751 | -4.07% | $1,558,274.00 |
| Northern Trust Corp | 31 Dec, 2025 | 865,708 | -36,751 | -4.07% | $1,558,274.00 |